Source: International Congress 2017 – Spanish and Portuguese Programme 2017



Rating:

Share or cite this content

Citations should be made in the following way:
M. Pretti Dalcolmo (Rio De Janeiro/Rj, Brazil). Would new drugs and regimens permit shorter TB treatments? Up to dateNovos fármacos e regimes permitiriam tratamentos mais curtos? Atualizar. International Congress 2017 – Spanish and Portuguese Programme 2017

Member's Comments

No comment yet.

Related content which might interest you: New drugs and drug regimens in the treatment of chronic and MDR-TB - what is on the horizon? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005 New short regimens for latent tuberculosis treatment: safety first! Source: Eur Respir J, 52 (6) 1802180; 10.1183/13993003.02180-2018 Year: 2018 Anti-tuberculosis drugs : what is new? / Nouveaux médicaments antituberculeux: quoi de neuf ? Source: International Congress 2018 – French Programme 2018: Part II Year: 2018 Has the time come to shorten TB treatment and TB preventive therapy? Source: Virtual Congress 2021 – Respiratory infections Year: 2021 Can asthma patients cope with new treatment regimens in Ukraine? Source: Eur Respir J 2003; 22: Suppl. 45, 409s Year: 2003 Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012 Getting approval for new therapeutic medical devices versus drugs: are the differences justified? Source: Eur Respir Rev 2016; 25: 223-226 Year: 2016 Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is the benefit? Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Evaluating disease-modifying treatment in CF: are we ready to take the challenge? Source: International Congress 2014 – Ceremony for the ERS Rare Pulmonary Disease Research Award 2014 followed by the symposium "Challenges in endpoints for rare lung diseases" Year: 2014 Second-line injectables: are they essential to treat MDR/XDR-TB cases? Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008 Tuberculosis elimination, patients' lives and rational use of new drugs: revisited Source: Eur Respir J 2016; 47: 664-667 Year: 2016 Opportunities of application of short regimens for MDR-TBat the expense of using intravenous administration of anti-TB drugs during intensive phase Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 How to manage side-effects of targeted therapies? Source: Annual Congress 2010 - PG7 Postgraduate Course: How to manage treatment complications of lung cancer Year: 2010 Intermittent regimens for tuberculosis treatment: Back to the Future? Source: Eur Respir J, 56 (3) 2002510; 10.1183/13993003.02510-2020 Year: 2020 Four-month regimens: are they feasible? Source: International Congress 2015 – Tuberculosis: short-course chemotherapy Year: 2015 Do we need new antibiotics? Source: Annual Congress 2009 - Antibiotics and the lung Year: 2009